This week Mad in America examines studies related to adverse events associated with antipsychotics and antidepressants, ...

In A Nutshell Researchers achieved 94% accuracy in identifying Alzheimer’s disease by analyzing bacterial infections, ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in ...

A fully integrated substance use disorders emergency department model in Stockholm generates significant post-acute treatment ...

Public health recommendations suggest individuals can resume normal activities 5 days after symptom cessation. However, our study finds that full recovery can take longer, indicating that delayed ...

Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 ...

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® ...